Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17538299 | 0.86 | LMNA (0.47) | CHEK1PDE4D | |
| SCHEMBL17538297 | 0.82 | SYK (0.48) | CHEK1PDE4D | |
| SCHEMBL16158416 | 0.81 | CYP19A1 (0.46) | PLK1CYP19A1CHEK1PDE4DCHRNA7 | |
| SCHEMBL16158418 | 0.80 | HRH3 (0.49) | CYP19A1MAOA | |
| SCHEMBL19067937 | 0.80 | PLK1 (0.40) | PLK1CYP19A1CHEK1PDE4DKDM1A | |
| SCHEMBL17531508 | 0.79 | PDE4D (0.40) | PLK1CYP19A1CHEK1PDE4D | |
| SCHEMBL17538359 | 0.79 | HCRTR2 (0.37) | MAOA | |
| SCHEMBL17538298 | 0.78 | MAOA (0.36) | MAOA | |
| SCHEMBL17538361 | 0.76 | FLT1 (0.40) | MAOA | |
| SCHEMBL4813423 | 0.72 | CHEK1 (0.48) | PLK1CYP19A1CHEK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-9694005-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160038476-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038476-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | PLK1 2782/4885CYP19A1 47/4885CHEK1 2807/4885 |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | PLK1 2782/4885CYP19A1 47/4885CHEK1 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.